(Q36027530)

11 August 2017

1 reference

title

Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials (English)

1 reference

11 August 2017

0 references

1 reference

Helen A Fletcher

0 references

Adrian V S Hill

1 reference

11 August 2017

Helen McShane

1 reference

11 August 2017

Ansar A Pathan

1 reference

11 August 2017

Clare R Sander

series ordinal

1 reference

11 August 2017

Nilu P Goonetilleke

series ordinal

1 reference

11 August 2017

language of work or name

1 reference

21 January 2005

1 reference

11 August 2017

1 reference

11 August 2017

1 reference

11 August 2017

issue

1-2

1 reference

11 August 2017

page(s)

47-52

1 reference

The global tuberculosis situation and the new control strategy of the World Health Organization

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.015

Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.015

Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.015

Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.015

gamma/delta and other unconventional T lymphocytes: what do they see and what do they do?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.015

CD1c-mediated T-cell recognition of isoprenoid glycolipids in Mycobacterium tuberculosis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.015

An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.015

Disseminated tuberculosis in interferon gamma gene-disrupted mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.015

A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.015

BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.015

Variation in protection by BCG: implications of and for heterologous immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.015

CD8+ T cell-mediated suppression of intracellular Mycobacterium tuberculosis growth in activated human macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.015

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.015

Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.015

Protective immunity against Mycobacterium tuberculosis induced by dendritic cells pulsed with both CD8(+)- and CD4(+)-T-cell epitopes from antigen 85A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.015

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.015

Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.015

Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.015

Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.015

Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.015

Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.015

Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.015

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.015

Pulmonary necrosis resulting from DNA vaccination against tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.015

10.1016/J.TUBE.2004.09.015

7 January 2021

Identifiers

DOI

1 reference

11 August 2017

1 reference